After decades of research, what was once labeled “undruggable” is now a beacon of therapeutic promise. We’ve developed a robust KRAS G12C preclinical assay platform, including advanced in vivo brain metastasis models, to support the next wave of targeted therapies and combination strategies. Our platform evaluates key molecular interactions and drug candidate blood-brain-barrier penetration.

Takashi Willebrand, Associate Director of Business Development, will also be on site to discuss how we can provide customized preclinical assay solutions to support your KRAS G12C therapeutic development.  Whether you’re planning ahead or just met us at the show, use the form below to connect with our team—we’d love to continue the conversation.

Check out our featured content:

• Orthotopic and Metastatic Brain Tumor Models

• Preclinical Prostate Cancer Mouse Models